We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Amarin (AMRN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 85.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRN has returned about 6.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 3.6%. This means that Amarin is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Amneal Pharmaceuticals (AMRX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 29.7%.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual stocks and currently sits at #147 in the Zacks Industry Rank. Stocks in this group have lost about 1.2% so far this year, so AMRN is performing better this group in terms of year-to-date returns.
In contrast, Amneal Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 135 stocks and is ranked #144. Since the beginning of the year, the industry has moved -8.7%.
Investors interested in the Medical sector may want to keep a close eye on Amarin and Amneal Pharmaceuticals as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Amarin (AMRN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 85.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRN has returned about 6.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 3.6%. This means that Amarin is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Amneal Pharmaceuticals (AMRX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 29.7%.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual stocks and currently sits at #147 in the Zacks Industry Rank. Stocks in this group have lost about 1.2% so far this year, so AMRN is performing better this group in terms of year-to-date returns.
In contrast, Amneal Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 135 stocks and is ranked #144. Since the beginning of the year, the industry has moved -8.7%.
Investors interested in the Medical sector may want to keep a close eye on Amarin and Amneal Pharmaceuticals as they attempt to continue their solid performance.